Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study

Title
Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study
Publication Date
2025-01
Author(s)
Beaglehole, Ben
Glue, Paul
Neehoff, Shona
Shadli, Shabah
( author )
OrcID: https://orcid.org/0000-0002-3607-3469
Email: sshadli@une.edu.au
UNE Id une-id:sshadli
McNaughton, Neil
Kimber, Bridget
Muirhead, Chrissie
de Bie, Aroha
Day-Brown, Rachel
Hughes-Medlicott, Natalie J
Type of document
Journal Article
Language
en
Entity Type
Publication
Publisher
Sage Publications Ltd
Place of publication
United Kingdom
DOI
10.1177/02698811241301215
UNE publication id
une:1959.11/64633
Abstract

Background: Obsessive-Compulsive Disorder (OCD) may respond to ketamine treatment.

Aim: To examine the responsiveness and tolerability of treatment-refractory OCD to intramuscular (IM) ketamine compared to IM fentanyl.

Methods: This was a randomised double-blind psychoactive-controlled study with single doses of racemic ketamine 0.5mg/kg, 1.0mg/kg or fentanyl 50µg (psychoactive control). Pre-dosing with 4mg oral ondansetron provided nausea prophylaxis. Eligible participants were aged between 18 and 50 years with severe treatment-resistant OCD. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Tolerability was measured with the Clinician-Administered Dissociative States Scale (CADSS). Repeated measures analysis of variance with orthogonal polynomial trends was used to assess the effect of drug treatment on Y-BOCS and CADSS scores.

Results: Twelve participants were randomised and 10 completed the study (7 females, 3 males, mean age 33years). Two participants dropped out due to not tolerating dissociative effects associated with the study medication. The reductions in Y-BOCS scores were greater and statistically dose-related for both ketamine doses than fentanyl (dose [linear], F(1, 9) =6.5, p=0.031). Score changes for all treatments were maximal at 1–2h with a steady separation of scores out to 168h. Ketamine was associated with short-term dissociative and cardiovascular effects.

Conclusions: We provide further preliminary evidence for the efficacy and tolerability of IM ketamine in an outpatient cohort of OCD. Additional work is required to establish the optimal dosing regimen and longer-term role of ketamine for OCD. These findings are encouraging given the well-known limitations that exist for treatments in this area.

Link
Citation
Journal of Psychopharmacology, 39(1), p. 23-28
ISSN
1461-7285
0269-8811
Start page
23
End page
28
Rights
Attribution 4.0 International

Files:

NameSizeformatDescriptionLink
openpublished/KetamineShadli2024JournalArticle.pdf 612.008 KB application/pdf Published Version View document